{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:23:53Z","timestamp":1780082633614,"version":"3.54.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10067-021-05841-1","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T01:02:20Z","timestamp":1624842140000},"page":"3411-3418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psoriatic arthritis in Africa"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-4328","authenticated-orcid":false,"given":"Ajesh B.","family":"Maharaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewale","family":"Adebajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"5841_CR1","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","volume":"141","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Weinstein R, Porter SB et al (2005) Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 141:1537\u20131541","journal-title":"Arch Dermatol"},{"key":"5841_CR2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2340\/0001555561344346","volume":"61","author":"F Brandrup","year":"1981","unstructured":"Brandrup F, Green A (1981) The prevalence of psoriasis in Denmark. Acta Derm Venereol 61:344\u2013346","journal-title":"Acta Derm Venereol"},{"key":"5841_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1468-3083.2001.00191.x","volume":"15","author":"C Ferrandiz","year":"2001","unstructured":"Ferrandiz C, Bordas X, Garcia-Patos V et al (2001) Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 15:20\u201323","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5841_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55\u201378","journal-title":"Semin Arthritis Rheum"},{"key":"5841_CR5","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P et al (2006) CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665\u201373","journal-title":"Arthritis Rheum"},{"key":"5841_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1046\/j.1365-2230.2003.01417.x","volume":"28","author":"ST Hartshorne","year":"2003","unstructured":"Hartshorne ST (2003) Dermatological disorders in Johannesburg, South Africa. Clin Exp Dermatol 28:661\u2013665. https:\/\/doi.org\/10.1046\/j.1365-2230.2003.01417.x","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"5841_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1046\/j.1365-4362.2001.01229.x","volume":"40","author":"PT Doe","year":"2001","unstructured":"Doe PT, Asiedu A, Acheampong JW, Rowland Payne CM (2001) Skin diseases in Ghana and the UK. Int J Dermatol 40(5):323\u2013326. https:\/\/doi.org\/10.1046\/j.1365-4362.2001.01229.x (PMID: 11554993)","journal-title":"Int J Dermatol"},{"issue":"1","key":"5841_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1365-4632.2004.01967.x","volume":"43","author":"AO Ogunbiyi","year":"2004","unstructured":"Ogunbiyi AO, Daramola OO, Alese OO (2004) Prevalence of skin diseases in Ibadan. Nigeria Int J Dermatol 43(1):31\u201336. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.01967.x","journal-title":"Nigeria Int J Dermatol"},{"key":"5841_CR9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/ard.40.4.366","volume":"40","author":"L Green","year":"1981","unstructured":"Green L, Meyers OL, Gordon W et al (1981) Arthritis in psoriasis. Ann Rheum Dis 40:366\u2013369","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5841_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jaad.2004.07.045","volume":"52","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Stern RS, Nijsten T et al (2005) The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 52(1):23\u201326. https:\/\/doi.org\/10.1016\/j.jaad.2004.07.045","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"5841_CR11","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10067-014-2763-3","volume":"34","author":"GS Kerr","year":"2015","unstructured":"Kerr GS, Qaiyumi S, Richards J, Vahabzadeh-Monshie H, Kindred C, Whelton S, Constantinescu F (2015) Psoriasis and psoriatic arthritis in African-American patients\u2013the need to measure disease burden. Clin Rheumatol 34(10):1753\u20131759. https:\/\/doi.org\/10.1007\/s10067-014-2763-3 (Epub 2014 Aug 28 PMID: 25164561)","journal-title":"Clin Rheumatol"},{"issue":"1","key":"5841_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/rheumatology\/keaa298","volume":"60","author":"Tariq Aslam","year":"2021","unstructured":"Aslam Tariq, Mahmood Farrouq, Sabanathan Anetha, Waxman Robin, Helliwell Philip S (2021) A clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds. Rheumatology. 60(1):340\u2013345. https:\/\/doi.org\/10.1093\/rheumatology\/keaa298","journal-title":"Rheumatology."},{"issue":"1","key":"5841_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jbspin.2011.06.007","volume":"79","author":"DD Ou\u00e9draogo","year":"2012","unstructured":"Ou\u00e9draogo DD, Meyer O (2012) Psoriatic arthritis in Sub-Saharan Africa. Joint Bone Spine 79(1):17\u201319. https:\/\/doi.org\/10.1016\/j.jbspin.2011.06.007","journal-title":"Joint Bone Spine"},{"issue":"1","key":"5841_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/08916930310001637986","volume":"37","author":"MR Namazi","year":"2004","unstructured":"Namazi MR (2004) Paradoxical exacerbation of psoriasis in AIDS: proposed explanations including the potential roles of substance P and gram-negative bacteria. Autoimmunity 37(1):67\u201371. https:\/\/doi.org\/10.1080\/08916930310001637986 (PMID: 15115314)","journal-title":"Autoimmunity"},{"key":"5841_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2471\/BLT.07.046474","volume":"86","author":"RM Scheffler","year":"2008","unstructured":"Scheffler RM, Liu XJ, Yohannes Kinfuc J et al (2008) Forecasting the global shortage of physicians: an economicand needs-based approach. Bull World Health Organ 86:516\u2013523","journal-title":"Bull World Health Organ"},{"key":"5841_CR16","doi-asserted-by":"crossref","unstructured":"WHO (2013) GBD 2010 country results: a global public good. Lancet 381(9871):965\u201370","DOI":"10.1016\/S0140-6736(13)60283-4"},{"issue":"5","key":"5841_CR17","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"Laura C Coates","year":"2016","unstructured":"Coates Laura C, Kavanaugh Arthur, Mease Philip J, at, (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 68(5):1060\u201371. https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"5841_CR18","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159.PMID:32434812;PMCID:PMC7286048","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159.PMID:32434812;PMCID:PMC7286048","journal-title":"Ann Rheum Dis"},{"key":"5841_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A et al (2019) 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & Rheumatology 71:5\u201332. https:\/\/doi.org\/10.1002\/art.40726","journal-title":"Arthritis & Rheumatology"},{"key":"5841_CR20","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s10067-020-04934-7","volume":"39","author":"M Elmamoun","year":"2020","unstructured":"Elmamoun M, Eraso M, Anderson M et al (2020) International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings. Clin Rheumatol 39:1839\u20131850. https:\/\/doi.org\/10.1007\/s10067-020-04934-7","journal-title":"Clin Rheumatol"},{"key":"5841_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5070\/D34SF63339","volume":"13","author":"DJ Fife","year":"2007","unstructured":"Fife DJ, Waller JM, Jeffes EW et al (2007) Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles. Dermatol Online J 13:4","journal-title":"Dermatol Online J"},{"key":"5841_CR22","unstructured":"Ortonne JP, Lebwohl M, Griffiths C; Alefacept Clinical Study Group (2003) Alefacept-induced decrease in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 13:117\u2013123"},{"key":"5841_CR23","doi-asserted-by":"crossref","unstructured":"Ellis CN, Krueger GG, Alefacept Clinical Study Group (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248\u2013255","DOI":"10.1056\/NEJM200107263450403"},{"issue":"9","key":"5841_CR24","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1097\/00002030-199709000-00005","volume":"11","author":"SA Klein","year":"1997","unstructured":"Klein SA, Dobmyer JM, Pape M et al (1997) Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 11(9):1111\u20131118. https:\/\/doi.org\/10.1097\/00002030-199709000-00005 (PMID: 9233457)","journal-title":"AIDS"},{"key":"5841_CR25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"LM Austin","year":"1999","unstructured":"Austin LM, Ozawa M, Kikuchi T et al (1999) The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-g, interleukin-2, and tumor necrosis factor-a, defining TC1 (cytotoxic T lymphocye) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113:752\u2013759","journal-title":"J Invest Dermatol"},{"key":"5841_CR26","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1046\/j.1523-1747.1998.00419.x","volume":"111","author":"SK Szabo","year":"1998","unstructured":"Szabo SK, Hammerberg C, Yoshida Y et al (1998) Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD41 and CD81 subsets. J Invest Dermatol 111:1072\u20131078","journal-title":"J Invest Dermatol"},{"key":"5841_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s004030000167","volume":"292","author":"M Friedrich","year":"2000","unstructured":"Friedrich M, Krammig S, Henze M et al (2000) Flow cytometric characterization of lesions T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory\/effector type 1 immunophenotype. Arch Dermatol Res 292:519\u2013521","journal-title":"Arch Dermatol Res"},{"key":"5841_CR28","doi-asserted-by":"publisher","unstructured":"Ou\u00e9draogo D-D, Meyer O. Psoriatic arthritis in Sub-Saharan Africa. Joint, Bone, Spine: Revue du Rhumatisme 79(1):17\u20139. https:\/\/doi.org\/10.1016\/j.jbspin.2011.06.007","DOI":"10.1016\/j.jbspin.2011.06.007"},{"issue":"3","key":"5841_CR29","first-page":"91","volume":"49","author":"A Gabla","year":"1997","unstructured":"Gabla A, Eti E, Nebavi Z et al (1997) Psoriatic arthritis in Ivory Coast - a report of 10 cases. Rhumatologie 49(3):91\u201394","journal-title":"Rhumatologie"},{"issue":"3","key":"5841_CR30","first-page":"506","volume":"23","author":"CM SteinP Davis","year":"1996","unstructured":"SteinP Davis CM (1996) Arthritis associated with HIV infection in Zimbabwe. J Rheumatol 23(3):506\u2013511","journal-title":"J Rheumatol"},{"key":"5841_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1046\/j.1365-2133.1998.02495.x","volume":"139","author":"E Mallon","year":"1998","unstructured":"Mallon E, Young D, Bunce M et al (1998) HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol 139:527\u2013533","journal-title":"Br J Dermatol"},{"issue":"7","key":"5841_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S1473-3099(10)70101-8","volume":"10","author":"N Morar","year":"2010","unstructured":"Morar N, Willis-Owen SA, Maurer T et al (2010) HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis. 10(7):470\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(10)70101-8","journal-title":"Lancet Infect Dis."},{"key":"5841_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","volume":"72","author":"A Jamnitski","year":"2013","unstructured":"Jamnitski A, Symmons D, Peters MJ et al (2013) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72:211\u2013216","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5841_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/acr.22926","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek A, Touma Z, Anderson M et al (2017) Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 69(1):67\u201374","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5841_CR35","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3899\/jrheum.140882","volume":"41","author":"A Ogdie","year":"2014","unstructured":"Ogdie A, Schwartzma S, Eder L et al (2014) Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol 41:2315\u20132322","journal-title":"J Rheumatol"},{"key":"5841_CR36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2013.01.011","volume":"68","author":"ED Dommasch","year":"2013","unstructured":"Dommasch ED, Troxel AB, Gelfand JM (2013) Major cardiovascular events associated with anti-IL 12\/23 agents: a tale of two meta-analyses. J Am Acad Dermatol 68:863\u2013865","journal-title":"J Am Acad Dermatol"},{"key":"5841_CR37","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/2013.jamadermatol.88","volume":"148","author":"M Lebwohl","year":"2012","unstructured":"Lebwohl M (2012) Interleukin 12\/23 agents and major adverse cardiovascular events. Arch Dermatol 148:1329","journal-title":"Arch Dermatol"},{"issue":"3","key":"5841_CR38","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.40366","volume":"70","author":"L Eder","year":"2018","unstructured":"Eder L, Joshi AA, Dey AK et al (2018) Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol 70(3):408\u2013416","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"5841_CR39","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1136\/annrheumdis-2015-208174","volume":"75","author":"A Molto","year":"2016","unstructured":"Molto A, Etcheto A, van der Heijde D et al (2016) Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA Study. Ann Rheum Dis 75(6):1016\u20131023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"5841_CR40","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han C, Robinson DW Jr, Hackett MV et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheum 33(11):2167\u20132172","journal-title":"J Rheum"},{"issue":"3","key":"5841_CR41","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480\u2013489","journal-title":"Ann Rheum Dis"},{"key":"5841_CR42","unstructured":"Bellou E, Verstappen SMM, Cook M, et al (2016) Increased rates of hypertension in patients with psoriatic arthritis compared to psoriasis alone: results from the UK Biobank [abstract]. Arthritis Rheumatol 68(suppl 10). http:\/\/acrabstracts.org\/abstract\/increased-rates-of-hypertension-in-patients-with-psoriatic-arthritis-compared-to-psoriasis-alone-results-from-the-uk-biobank. Accessed 28 Sept 2016"},{"issue":"1","key":"5841_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5455\/medarh.2015.69.13-15","volume":"69","author":"EM Salihbegovic","year":"2015","unstructured":"Salihbegovic EM, Hadzigrahic N, Suljagic E et al (2015) Psoriasis and high blood pressure. Med Arch. 69(1):13\u20135. https:\/\/doi.org\/10.5455\/medarh.2015.69.13-15","journal-title":"Med Arch."},{"key":"5841_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11883-013-0311-2","volume":"15","author":"C Recarti","year":"2013","unstructured":"Recarti C, Unger T (2013) Prevention of coronary artery disease: recent advances in the management of hypertension. Curr Atheroscler Rep 15:311","journal-title":"Curr Atheroscler Rep"},{"key":"5841_CR45","unstructured":"American Heart Association, Diet, and Lifestyle Recommendations 2014 [Internet. Accessed August 7, 2014]; Available from: http:\/\/www.heart.org\/HEARTORG\/GettingHealthy\/NutritionCenter\/HealthyEating\/The-American-Heart-Associations-Diet-and-LifestyleRecommendations_UCM_305855_Article.jsp"},{"issue":"33","key":"5841_CR46","first-page":"1635","volume":"2012","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H et al (2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012(33):1635\u20131701","journal-title":"Eur Heart J"},{"issue":"10","key":"5841_CR47","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/j.1468-3083.2007.02260.x","volume":"21","author":"M Akhyani","year":"2007","unstructured":"Akhyani M, Ehsani AH, Robati RM et al (2007) The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 21(10):1330\u20131332","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"5841_CR48","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1136\/ard.59.11.904","volume":"59","author":"S Jones","year":"2000","unstructured":"Jones S, Harris C, Lloyd J et al (2000) Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 59(11):904\u2013909","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5841_CR49","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","volume":"47","author":"LS Tam","year":"2008","unstructured":"Tam LS, Tomlinson B, Chu TT et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls\u2013the role of inflammation. Rheumatology (Oxford) 47(5):718\u2013723","journal-title":"Rheumatology (Oxford)"},{"key":"5841_CR50","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/annrheumdis-2011-201273","volume":"71","author":"W Li","year":"2012","unstructured":"Li W, Han J, Qureshi AA (2012) Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 71:1267\u20131272","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5841_CR51","first-page":"19","volume":"9","author":"C Popescu","year":"2014","unstructured":"Popescu C, Pintilie AM, Bojinca V, Balanescu A, Ionescu R (2014) Cardiovascular risk in psoriatic arthritis - a cross-sectional study. Maedica (Bucur). 9(1):19\u201324","journal-title":"Maedica (Bucur)."},{"key":"5841_CR52","doi-asserted-by":"publisher","unstructured":"Myasoedova E, Akkara Veetil BM, Matteson EL et al (2013) Cardiovascular risk in psoriasis: a population-based analysis with assessment of the framingham risk score. Scientifica 371569. https:\/\/doi.org\/10.1155\/2013\/371569","DOI":"10.1155\/2013\/371569"},{"issue":"11","key":"5841_CR53","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1136\/annrheumdis-2013-203433","volume":"73","author":"L Eder","year":"2014","unstructured":"Eder L, Chandran V, Gladman DD (2014) The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 73(11):1990\u20131996","journal-title":"Ann Rheum Dis"},{"key":"5841_CR54","doi-asserted-by":"crossref","unstructured":"Caso F, Del Puente A, Oliviero F, et al (2018) Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol 37(3):579\u2013586","DOI":"10.1007\/s10067-017-3975-0"},{"key":"5841_CR55","doi-asserted-by":"publisher","unstructured":"Goolam Mahyoodeen N, Crowther NJ, Snyman T et al High burden of the metabolic syndrome and its component disorders in South Africans with psoriasis. Int J Dermatol 58:557\u2013562. https:\/\/doi.org\/10.1111\/ijd.14348","DOI":"10.1111\/ijd.14348"},{"key":"5841_CR56","doi-asserted-by":"crossref","unstructured":"Dreiher J, Freud T, and Cohen AD. Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract. 2013; 2013: 580404. Published online 2013 Jun 17","DOI":"10.1155\/2013\/580404"},{"key":"5841_CR57","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1136\/ard.2009.125476","volume":"69","author":"DH Solomon","year":"2010","unstructured":"Solomon DH, Love TJ, Canning C et al (2010) Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Ann Rheum Dis 69:2114\u20132117","journal-title":"Ann Rheum Dis"},{"key":"5841_CR58","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/jdv.12001","volume":"27","author":"S Kumar","year":"2013","unstructured":"Kumar S, Han J, Li T, Qureshi AA (2013) Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 27:1293\u20131298","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"5841_CR59","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jaad.2006.09.017","volume":"56","author":"J Shapiro","year":"2007","unstructured":"Shapiro J, Cohen AD, David M et al (2007) The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56(4):629\u2013634","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"5841_CR60","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.160861","volume":"44","author":"L Eder","year":"2017","unstructured":"Eder L, Chandran V, Cook R et al (2017) The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study. J Rheumatol 44(3):286\u2013291","journal-title":"J Rheumatol"},{"key":"5841_CR61","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/bmj.291.6501.999","volume":"291","author":"G Kavli","year":"1985","unstructured":"Kavli G, Forde OH, Arnesen E et al (1985) Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed) 291:999\u20131000","journal-title":"Br Med J (Clin Res Ed)"},{"key":"5841_CR62","unstructured":"Braathen LR, Botten G, Bjerkedal T (1989) Psoriatics in Norway. A questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption. Acta Derm Venereol Suppl (Stockh) 142:9\u201312"},{"key":"5841_CR63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2133.1992.tb14818.x","volume":"127","author":"CM Mills","year":"1992","unstructured":"Mills CM, Srivastava ED, Harvey IM et al (1992) Smoking habits in psoriasis: a case control study. Br J Dermatol 127:18\u201321","journal-title":"Br J Dermatol"},{"issue":"6","key":"5841_CR64","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/annrheumdis-2011-200416","volume":"71","author":"W Li","year":"2012","unstructured":"Li W, Han J, Qureshi AA (2012) Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 71(6):804\u2013808. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200416","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5841_CR65","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/ard.2010.147793","volume":"71","author":"L Eder","year":"2012","unstructured":"Eder L, Shanmugarajah S, Thavaneswaran A et al (2012) The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis 71(2):219\u2013224. https:\/\/doi.org\/10.1136\/ard.2010.147793","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5841_CR66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2017-211625","volume":"77","author":"UDT Nguyen","year":"2018","unstructured":"Nguyen UDT, Zhang Y, Lu N et al (2018) Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Ann Rheum Dis 77(1):119\u2013123","journal-title":"Ann Rheum Dis"},{"key":"5841_CR67","doi-asserted-by":"publisher","unstructured":"Kaine J, Song X, Kim G, Hur P, Palmer JB (2019) Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. Administrative Claims Data. J Manag Care Spec Pharm 25(1):122\u2013132. https:\/\/doi.org\/10.18553\/jmcp.2018.17421","DOI":"10.18553\/jmcp.2018.17421"},{"issue":"12","key":"5841_CR68","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1136\/annrheumdis-2014-205389","volume":"74","author":"P H\u00f8jgaard","year":"2015","unstructured":"H\u00f8jgaard P, Glintborg B, Hetland ML et al (2015) Association between tobacco smoking and response to tumour necrosis factor \u03b1 inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis 74(12):2130\u20132136","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5841_CR69","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2340\/00015555-2657","volume":"97","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Thyssen JP, Jensen P et al (2017) Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: a nationwide cohort study. Acta Derm Venereol 97(7):819\u2013824","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"5841_CR70","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ejhf.113","volume":"16","author":"U Khalid","year":"2014","unstructured":"Khalid U, Ahlehoff O, Gislason GH et al (2014) Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail 16(7):743\u2013748","journal-title":"Eur J Heart Fail"},{"key":"5841_CR71","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH et al (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133\u20133140","journal-title":"Circulation"},{"issue":"10","key":"5841_CR72","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/jid.2009.112","volume":"129","author":"JM Gelfand","year":"2009","unstructured":"Gelfand JM, Dommasch E, Shin BD et al (2009) The risk of stroke in patients with psoriasis. J Invest Dermatol 129(10):2411\u20132418. https:\/\/doi.org\/10.1038\/jid.2009.112","journal-title":"J Invest Dermatol"},{"key":"5841_CR73","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1002\/art.34524","volume":"64","author":"AG Semb","year":"2012","unstructured":"Semb AG, Kvien TK, DeMicco DA et al (2012) Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 64:2836\u20132846","journal-title":"Arthritis Rheum"},{"key":"5841_CR74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","volume":"20","author":"WH Boehncke","year":"2011","unstructured":"Boehncke WH, Boehncke S, Tobin AM et al (2011) The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20:303\u2013307","journal-title":"Exp Dermatol"},{"issue":"3","key":"5841_CR75","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3899\/jrheum.170379","volume":"45","author":"L Eder","year":"2018","unstructured":"Eder L, Harvey P, Chandran V et al (2018) Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study. J Rheumatol 45(3):378\u2013384","journal-title":"J Rheumatol"},{"key":"5841_CR76","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/qjmed\/hcg138","volume":"96","author":"N O\u2019Connor","year":"2003","unstructured":"O\u2019Connor N, Dargan PI, Jones AL (2003) Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM 96:787\u2013791","journal-title":"QJM"},{"key":"5841_CR77","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/ard.2009.112136","volume":"69","author":"J Sokolove","year":"2010","unstructured":"Sokolove J, Strand V, Greenberg JD et al (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69:1612\u20131617","journal-title":"Ann Rheum Dis"},{"key":"5841_CR78","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1136\/ard.2009.116194","volume":"69","author":"M Seitz","year":"2010","unstructured":"Seitz M, Reichenbach S, Moller B et al (2010) Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 69:1148\u20131150","journal-title":"Ann Rheum Dis"},{"key":"5841_CR79","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/rheumatology\/kep176","volume":"48","author":"H Amital","year":"2009","unstructured":"Amital H, Arnson Y, Chodick G et al (2009) Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology 48:1107\u20131110","journal-title":"Rheumatology"},{"key":"5841_CR80","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.2008.101378","volume":"69","author":"JR Curtis","year":"2010","unstructured":"Curtis JR, Beukelman T, Onofrei A et al (2010) Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide. Ann Rheum Dis 69:43\u201347","journal-title":"Ann Rheum Dis"},{"key":"5841_CR81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00044011-200626020-00001","volume":"26","author":"L Tilling","year":"2006","unstructured":"Tilling L, Townsend S, David J (2006) Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Invest 26:55\u201362","journal-title":"Clin Drug Invest"},{"issue":"4","key":"5841_CR82","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","volume":"138","author":"A Ogdie","year":"2018","unstructured":"Ogdie A, Grewal SK, Noe MH, Shin DB, Takeshita J, Chiesa Fuxench ZC, Carr RM, Gelfand JM (2018) Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. J Invest Dermatol 138(4):760\u2013767","journal-title":"J Invest Dermatol"},{"issue":"4","key":"5841_CR83","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jid.2016.11.032","volume":"137","author":"RT Lewinson","year":"2017","unstructured":"Lewinson RT, Vallerand IA, Lowerison MW et al (2017) Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-based study. J Invest Dermatol 137(4):828\u2013835","journal-title":"J Invest Dermatol"},{"issue":"5","key":"5841_CR84","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.130797","volume":"41","author":"E McDonough","year":"2014","unstructured":"McDonough E, Ayearst R, Eder L et al (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheum 41(5):887\u2013896","journal-title":"J Rheum"},{"issue":"4","key":"5841_CR85","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/acr.23333","volume":"70","author":"C Ballegaard","year":"2018","unstructured":"Ballegaard C, H\u00f8jgaard P, Dreyer L et al (2018) Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 70(4):592\u2013599","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"5841_CR86","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.semarthrit.2016.03.003","volume":"46","author":"MN Magrey","year":"2016","unstructured":"Magrey MN, Lewis S, Asim KM (2016) Utility of DXA scanning and risk factors for osteoporosis in ankylosing spondylitis\u2014a prospective study. Semin Arthritis Rheum 46(1):88\u201394","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5841_CR87","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.semarthrit.2016.05.005","volume":"46","author":"S Chandran","year":"2016","unstructured":"Chandran S, Aldei A, Johnson SR et al (2016) Prevalence and risk factors of low bone mineral density in psoriatic arthritis: a systematic review. Semin Arthritis Rheum 46(2):174\u2013182","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"5841_CR88","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/art.30310","volume":"63","author":"AE Thompson","year":"2011","unstructured":"Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63(6):1479\u20131485. https:\/\/doi.org\/10.1002\/art.30310","journal-title":"Arthritis Rheum"},{"key":"5841_CR89","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/art.23185","volume":"58","author":"S Rohekar","year":"2008","unstructured":"Rohekar S, Tom BD, Hassa A et al (2008) Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 58:82\u201387","journal-title":"Arthritis Rheum"},{"key":"5841_CR90","doi-asserted-by":"crossref","unstructured":"Ogdie A, Maliha S, Love T, et al (2017) Cause-specific mortality in patients with psoriatic arthritis Rheumatology (Oxford) 56(6):907\u2013911","DOI":"10.1093\/rheumatology\/kew502"},{"key":"5841_CR91","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","volume":"76","author":"K Hellgren","year":"2017","unstructured":"Hellgren K, Dreyer L, Arkema EV et al (2017) Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis 76:105\u2013111","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5841_CR92","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V et al (2015) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 74(5):813\u2013817","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5841_CR93","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s10067-017-3769-4","volume":"36","author":"MS Chimenti","year":"2017","unstructured":"Chimenti MS, Triggianese P, Conigliaro P et al (2017) A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. Clin Rheumatol 36(10):2253\u20132260","journal-title":"Clin Rheumatol"},{"key":"5841_CR94","doi-asserted-by":"crossref","unstructured":"Di Minno MN, Peluso R, Iervolino S, et al (2014) CaRRDs Study Group. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers. Ann Rheum Dis 73(6):1157\u201362","DOI":"10.1136\/annrheumdis-2012-202812"},{"issue":"8","key":"5841_CR95","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 51(8):1368\u201377. https:\/\/doi.org\/10.1093\/rheumatology\/kes001","journal-title":"Rheumatology (Oxford)."},{"issue":"5","key":"5841_CR96","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/rheumatology\/key369","volume":"58","author":"SK Appani","year":"2019","unstructured":"Appani SK, Devarasetti PK, Irlapati RVP, al. et al (2019) Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis. Rheumatology 58(5):869\u2013873. https:\/\/doi.org\/10.1093\/rheumatology\/key369","journal-title":"Rheumatology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05841-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05841-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05841-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T10:38:35Z","timestamp":1699180715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05841-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5841"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05841-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}